Sartorius Stedim Biotech SA
DIM: XPAR (FRA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€828.00 | Jwl | Bjgbjmvx |
Wide-Moat Sartorius Stedim Has Decent Q2 With Higher Sales Offset by Flat Margin; Shares Overvalued
Wide-moat Sartorius Stedim (Sartorius AG’s bioprocess subsidiary) had an overall good first quarter and stayed on track to generally meet our targets. We are slightly adjusting our short-term expectations, though our long-term forecasts are unchanged, and we maintain our EUR 290 fair value estimate.